Analysis of KIT expression and gene mutation in human acral melanoma: With a comparison between primary tumors and corresponding metastases/recurrences

Human Pathology

Volumn 44, Issue 8, 2013, Pages 1472-1478

  Dai, Bo ^a,b   Cai, Xu ^a,b   Kong, Yun Yi ^a,b   Yang, Fei ^a,b   Shen, Xu Xia ^a,b   Wang, Li Wei ^a,b   Kong, Jin Cheng ^c  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Acral; Immunohistochemistry; KIT; Melanoma; Mutation

Indexed keywords

STEM CELL FACTOR;

ACRAL MELANOMA; ADULT; AGED; ARTICLE; CLINICAL FEATURE; COMPARATIVE STUDY; CORRELATION ANALYSIS; CYTOPLASM; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; MITOSIS; MITOSIS RATE; PRIMARY TUMOR; SKIN METASTASIS; SKIN ULCER; TUMOR RECURRENCE;

ACRAL; IMMUNOHISTOCHEMISTRY; KIT; MELANOMA; MUTATION;

ADULT; AGED; AGED, 80 AND OVER; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-KIT; RECURRENCE; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84880325282     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2013.01.007     Document Type: Article

References (29)

1. Y. Kong, S.M. Kumar, and X. Xu Molecular pathogenesis of sporadic melanoma and melanoma-initiating cells Arch Pathol Lab Med 134 2010 1740 1749
2. P.E. LeBoit, G. Burg, D. Weedon, and A. Sarasin World Health Organization Classification of Tumours 3rd ed 2006 IARC Press 73
3. Z. Chi, S. Li, and X. Sheng Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases BMC Cancer 11 2011 85
4. M.L. Wallander, L.J. Layfield, and L.L. Emerson KIT mutations in ocular melanoma: frequency and anatomic distribution Mod Pathol 24 2011 1031 1035
5. C. Beadling, E. Jacobson-Dunlop, and F.S. Hodi KIT gene mutations and copy number in melanoma subtypes Clin Cancer Res 14 2008 6821 6828
6. J.M. Grichnik, J.A. Burch, J. Burchette, and C.R. Shea The SCF/KIT pathway plays a critical role in the control of normal human melanocyte homeostasis J Invest Dermatol 111 1998 233 238
7. Y. Kong, L. Si, and Y. Zhu Large-scale analysis of KIT aberrations in Chinese patients with melanoma Clin Cancer Res 17 2011 1684 1691
8. A. Ashida, M. Takata, H. Murata, K. Kido, and T. Saida Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas Int J Cancer 124 2009 862 868
9. N.L. Schoenewolf, C. Bull, and B. Belloni Sinonasal, genital and acrolentiginous melanomas show distinct characteristics of KIT expression and mutations Eur J Cancer 48 2012 1842 1852
10. C.A. Torres-Cabala, W.L. Wang, and J. Trent Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type Mod Pathol 22 2009 1446 1456
11. J. Yun, J. Lee, and J. Jang KIT amplification and gene mutations in acral/mucosal melanoma in Korea APMIS 119 2011 330 335
12. R.D. Carvajal, C.R. Antonescu, and J.D. Wolchok KIT as a therapeutic target in metastatic melanoma JAMA 305 2011 2327 2334
13. J.A. Curtin, K. Busam, D. Pinkel, and B.C. Bastian Somatic activation of KIT in distinct subtypes of melanoma J Clin Oncol 24 2006 4340 4346
14. S. Ni, D. Huang, and X. Chen c-kit gene mutation and CD117 expression in human anorectal melanomas Hum Pathol 43 2012 801 807
15. C.M. Balch, J.E. Gershenwald, and S.J. Soong Final version of 2009 AJCC melanoma staging and classification J Clin Oncol 27 2009 6199 6206
16. J.W. Chang, K.Y. Yeh, and C.H. Wang Malignant melanoma in Taiwan: a prognostic study of 181 cases Melanoma Res 14 2004 537 541
17. K. Ishihara, T. Saida, F. Otsuka, and N. Yamazaki Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update Int J Clin Oncol 13 2008 33 41
18. K. Ishihara, T. Saida, and A. Yamamoto Updated statistical data for malignant melanoma in Japan Int J Clin Oncol 6 2001 109 116
19. P.T. Bradford, A.M. Goldstein, M.L. McMaster, and M.A. Tucker Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005 Arch Dermatol 145 2009 427 434
20. E.T. Krementz, R.J. Feed, W.P. Coleman III, C.M. Sutherland, R.D. Carter, and M. Campbell Acral lentiginous melanoma. A clinicopathologic entity Ann Surg 195 1982 632 645
21. F. Janku, J. Novotny, and I. Julis KIT receptor is expressed in more than 50% of early-stage malignant melanoma: a retrospective study of 261 patients Melanoma Res 15 2005 251 256
22. Y. Funasaka, T. Boulton, and M. Cobb c-Kit-kinase induces a cascade of protein tyrosine phosphorylation in normal human melanocytes in response to mast cell growth factor and stimulates mitogen-activated protein kinase but is down-regulated in melanomas Mol Biol Cell 3 1992 197 209
23. A. Ohashi, Y. Funasaka, M. Ueda, and M. Ichihashi c-KIT receptor expression in cutaneous malignant melanoma and benign melanotic naevi Melanoma Res 6 1996 25 30
24. K.T. Montone, P. van Belle, R. Elenitsas, and D.E. Elder Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression Mod Pathol 10 1997 939 944
25. O. Nyormoi, and M. Bar-Eli Transcriptional regulation of metastasis-related genes in human melanoma Clin Exp Metastasis 20 2003 251 263
26. C.R. Antonescu, P. Besmer, and T. Guo Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation Clin Cancer Res 11 2005 4182 4190
27. A. Kalikaki, A. Koutsopoulos, and M. Trypaki Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC Br J Cancer 99 2008 923 929
28. I. Albanese, A.G. Scibetta, and M. Migliavacca Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations Biochem Biophys Res Commun 325 2004 784 791
29. Z.Y. Chen, W.Z. Zhong, and X.C. Zhang EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas Oncologist 17 2012 978 985